Authentication and Pharmaceutical Protection: An Industry Roundtable - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Authentication and Pharmaceutical Protection: An Industry Roundtable
PharmTech talked to anticounterfeiting experts to discuss terrorism as a source of counterfeit products.

Pharmaceutical Technology
Volume 34, Issue 9, pp. 42-48

On-dose authentication technology

Placing authentication technology directly on the dosage form allows drug manufacturers to identify counterfeit or substandard drugs that have entered the supply chain. On-dose technology uses physical chemical identifiers (PCIDs) such as inks, pigments, flavors, and molecular taggants containing unique properties. The US Food and Drug Administration released a draft guidance for industry, Incorporation of Physical Chemical Identifiers into Solid Oral Dosage Form Drug Pro ducts for Anti-counterfeitingin July 2009. Pharmaceutical Technology discussed the use of PCIDs and the draft guidance with John D'Ottavio, quality and regulatory affairs manager for ARmark Authentication Technologies (Glen Rock, PA), a provider of custom authentication systems to fight counterfeiting, and Dean Hart, executive vice-president of NanoGuardian.

PharmTech: What are the challenges a manufacturer may face when implementing PCIDs in terms of cost, operation, or other issues?

D'Ottavio: The major challenges that we have seen are related to the control of knowledge regarding the use of a PCID (i.e., who within the company should have knowledge of its use) and the breadth of scale to implement a PCID technology (i.e., on which products and regional versus global use). ARmark sells and markets the covert micro-tag PCIDs as a specialty excipient, a decision that has enabled us to avoid cost hurdles associated with licensing. In addition, adopting covert micro-tag technology does not require any incremental capital expenditure because it is an additional excipient that is added during re-constitution of the film coating. For these reasons, cost has not been a prohibitive factor in the acceptance of this technology.

PharmTech: What can a manufacturer do in advance to ease implementation?

D'Ottavio: Manufacturers of drug products can perform risk analyses to identify the products at greatest risk for counterfeiting to prioritize the implementation of PCID technologies. Additionally, controlling the knowledge of the use of PCIDs is paramount for covert security features, and therefore, internal communication, as well as external communication, should be limited to a "need-to-know" basis.

PharmTech: Can you discuss the impact of the PCID draft guidance on industry's anticounterfeiting efforts?

Hart: It is obvious that FDA sees the importance of on-dose technologies in the fight against counterfeiting and illegal diversion. Although FDA guidance is certainly needed when manufacturers are adding any type of chemical substance to a product, we are hopeful that the final FDA guidance will not be relegated to PCIDs only, but rather expanded to include more advanced on-dose technologies such as forensic markers, which add nothing to the dose yet provide equal, if not more comprehensive, protection against counterfeiting and illegal diversion given its layered security.

PharmTech: How can the pharmaceutical industry protect itself and consumers from counterfeit drugs?

D'Ottavio: Protecting the dosage itself, which is ingested by the patient, should be a critical concern in the hierarchy of counterfeit-resistant technologies. Protection must start with the identification and authentication of the dosage form because the distribution process for drugs involves repackaging, which is a vulnerable point for counterfeit product introduction.

Counterfeit-resistant technologies for protecting the package and supply chain will be far more effective when the dosage itself is also protected with on-dosage identification and authentication technology.

Hart: Manufacturers must realize that the enemy in this war is highly motivated, connected, and resourced. Traditional methods of brand protection, while still valuable, are waning in benefit. It is a new-age battle that requires manufacturers to fight with everything at their disposal, including state-of-the art technologies that protect the integrity and therapeutic benefit of each and every dose.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here